Patient-reported perceptions of brexanolone in the treatment of postpartum depression: A qualitative analysis.

Aaron Salwan, Megan Maroney, Lisa Tremayne
{"title":"Patient-reported perceptions of brexanolone in the treatment of postpartum depression: A qualitative analysis.","authors":"Aaron Salwan,&nbsp;Megan Maroney,&nbsp;Lisa Tremayne","doi":"10.9740/mhc.2022.12.342","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Brexanolone demonstrates short-term efficacy for the treatment of postpartum depression (PPD). Postpartum depression is linked to infanticide and maternal suicide, and current treatment often fails to adequately control depressive symptoms. The purpose of this analysis is to further understand the experience(s) of women who have received brexanolone for the treatment of PPD.</p><p><strong>Methods: </strong>Semistructured interviews modeled after the theory of planned behavior (TPB) were conducted to assess women's perceptions of treatment for PPD with brexanolone. Women who received treatment with brexanolone at this inpatient facility were eligible to participate in this study. The TPB is often used to predict intention to perform health-related behaviors. Semistructured interviews were recorded and transcribed, and thematic analysis was conducted to identify common ideas across all interviews. Follow-up assessment of depressive and anxious symptoms was also conducted using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7), respectively.</p><p><strong>Results: </strong>Five of the 10 women who received treatment with brexanolone at this facility were interviewed, and common themes related to the TPB were analyzed. Attitudes toward brexanolone were favorable, and having a strong support system was a motivating factor in receiving treatment for PPD. Insurance approval, need for childcare, and poor understanding of symptoms of PPD were barriers to receiving treatment with brexanolone. Symptoms of depression and anxiety were rated as low at the time of the follow-up interview as measured by the PHQ-9 (mean 1.6, range 1 to 3) and GAD-7 (mean 2.8, range 2 to 4), respectively.</p><p><strong>Discussion: </strong>Brexanolone rapidly and sustainably reduced symptoms of PPD and was well-received by patients. Despite significant barriers to use, women who received treatment with brexanolone advocated for its availability as well as increased awareness of PPD.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"12 6","pages":"342-349"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/35/i2168-9709-12-6-342.PMC9819138.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/mhc.2022.12.342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: Brexanolone demonstrates short-term efficacy for the treatment of postpartum depression (PPD). Postpartum depression is linked to infanticide and maternal suicide, and current treatment often fails to adequately control depressive symptoms. The purpose of this analysis is to further understand the experience(s) of women who have received brexanolone for the treatment of PPD.

Methods: Semistructured interviews modeled after the theory of planned behavior (TPB) were conducted to assess women's perceptions of treatment for PPD with brexanolone. Women who received treatment with brexanolone at this inpatient facility were eligible to participate in this study. The TPB is often used to predict intention to perform health-related behaviors. Semistructured interviews were recorded and transcribed, and thematic analysis was conducted to identify common ideas across all interviews. Follow-up assessment of depressive and anxious symptoms was also conducted using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7), respectively.

Results: Five of the 10 women who received treatment with brexanolone at this facility were interviewed, and common themes related to the TPB were analyzed. Attitudes toward brexanolone were favorable, and having a strong support system was a motivating factor in receiving treatment for PPD. Insurance approval, need for childcare, and poor understanding of symptoms of PPD were barriers to receiving treatment with brexanolone. Symptoms of depression and anxiety were rated as low at the time of the follow-up interview as measured by the PHQ-9 (mean 1.6, range 1 to 3) and GAD-7 (mean 2.8, range 2 to 4), respectively.

Discussion: Brexanolone rapidly and sustainably reduced symptoms of PPD and was well-received by patients. Despite significant barriers to use, women who received treatment with brexanolone advocated for its availability as well as increased awareness of PPD.

Abstract Image

患者报告的布雷沙诺酮治疗产后抑郁症的看法:定性分析。
简介:布雷沙诺酮对产后抑郁症(PPD)有短期疗效。产后抑郁症与杀婴和母亲自杀有关,目前的治疗往往不能充分控制抑郁症状。本分析的目的是进一步了解接受布雷沙诺酮治疗产后抑郁症的妇女的经历。方法:采用计划行为理论(TPB)模型进行半结构化访谈,评估女性对布雷沙诺酮治疗PPD的看法。在该住院机构接受布雷沙诺酮治疗的妇女有资格参加本研究。TPB常用于预测执行健康相关行为的意愿。对半结构化访谈进行记录和转录,并进行主题分析,以确定所有访谈中的共同观点。抑郁和焦虑症状的随访评估也分别使用患者健康问卷-9 (PHQ-9)和广泛性焦虑障碍-7 (GAD-7)进行。结果:在该机构接受布雷沙诺酮治疗的10名妇女中有5名接受了访谈,并分析了与TPB相关的共同主题。对布雷沙诺酮的态度是有利的,拥有强大的支持系统是接受PPD治疗的激励因素。保险批准、需要儿童保育和对PPD症状了解不足是接受布雷沙诺酮治疗的障碍。通过PHQ-9(平均1.6,范围1至3)和GAD-7(平均2.8,范围2至4)测量,随访访谈时抑郁和焦虑症状被评为低。讨论:布雷沙诺酮能快速、持续地减轻PPD的症状,并受到患者的好评。尽管在使用方面存在重大障碍,接受布雷沙诺酮治疗的妇女仍主张使用布雷沙诺酮,并提高对产后抑郁症的认识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信